194 related articles for article (PubMed ID: 24731689)
1. A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand.
Tantai N; Chaikledkaew U; Tanwandee T; Werayingyong P; Teerawattananon Y
BMC Health Serv Res; 2014 Apr; 14():170. PubMed ID: 24731689
[TBL] [Abstract][Full Text] [Related]
2. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.
Dakin H; Sherman M; Fung S; Fidler C; Bentley A
Pharmacoeconomics; 2011 Dec; 29(12):1075-91. PubMed ID: 22077579
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection.
Jones J; Colquitt J; Shepherd J; Harris P; Cooper K
Health Technol Assess; 2010 May; 14 Suppl 1():23-9. PubMed ID: 20507800
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China.
Wu B; Shen J; Cheng H
BMC Health Serv Res; 2012 Nov; 12():385. PubMed ID: 23137013
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B.
Veenstra DL; Sullivan SD; Clarke L; Iloeje UH; Tafesse E; Di Bisceglie A; Kowdley KV; Gish RG
Pharmacoeconomics; 2007; 25(11):963-77. PubMed ID: 17960954
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis.
Wu B; Li T; Chen H; Shen J
Value Health; 2010 Aug; 13(5):592-600. PubMed ID: 20561341
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China.
Ke W; Zhang C; Liu L; Gao Y; Yao Z; Ye X; Zhou S; Yang Y
Hepatol Int; 2016 Nov; 10(6):924-936. PubMed ID: 27271357
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore.
Lacey LF; Gane E
J Viral Hepat; 2007 Nov; 14(11):751-66. PubMed ID: 17927611
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of treatments for chronic hepatitis B.
Wiens A; Lenzi L; Venson R; Pedroso ML; Correr CJ; Pontarolo R
Braz J Infect Dis; 2013; 17(4):418-26. PubMed ID: 23849851
[TBL] [Abstract][Full Text] [Related]
11. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis.
Kanwal F; Gralnek IM; Martin P; Dulai GS; Farid M; Spiegel BM
Ann Intern Med; 2005 May; 142(10):821-31. PubMed ID: 15897532
[TBL] [Abstract][Full Text] [Related]
12. Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis.
Veenstra DL; Spackman DE; Di Bisceglie A; Kowdley KV; Gish RG
Aliment Pharmacol Ther; 2008 Jun; 27(12):1240-52. PubMed ID: 18373637
[TBL] [Abstract][Full Text] [Related]
13. HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan.
Veenstra DL; Sullivan SD; Lai MY; Lee CM; Tsai CM; Patel KK
Value Health; 2008; 11(2):131-8. PubMed ID: 18380625
[TBL] [Abstract][Full Text] [Related]
14. [An economic evaluation of different treatments for HBeAg-positive chronic hepatitis B in China].
Larry L; Lu XZ; Alison T
Zhonghua Gan Zang Bing Za Zhi; 2007 Jun; 15(6):431-6. PubMed ID: 17594808
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of chronic hepatitis B treatments in Taiwan.
Lacey L; Chien RN; Chuang WL; Pwu RF
J Gastroenterol Hepatol; 2008 Apr; 23(4):571-9. PubMed ID: 18397486
[TBL] [Abstract][Full Text] [Related]
16. Tenofovir
Rodríguez M; Pascasio JM; Fraga E; Fuentes J; Prieto M; Sánchez-Antolín G; Calleja JL; Molina E; García-Buey ML; Blanco MÁ; Salmerón J; Bonet ML; Pons JA; González JM; Casado MÁ; Jorquera F;
World J Gastroenterol; 2017 Nov; 23(41):7459-7469. PubMed ID: 29151700
[TBL] [Abstract][Full Text] [Related]
17. Incorporated antivirals for chronic hepatitis B in Brazil: a cost-effectiveness analysis.
Oliveira GL; Almeida AM; Silva AL; Brandão CM; Andrade EI; Cherchiglia ML; Acurcio Fde A
Rev Saude Publica; 2013 Aug; 47(4):769-78; discussion 779. PubMed ID: 24346678
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of the cost-effectiveness of antiviral therapies in chronic hepatitis B patients in Korea].
Kim BK; Kwon SY; Lee CH; Choe WH; Choi HM; Koo HW
Korean J Hepatol; 2009 Mar; 15(1):25-41. PubMed ID: 19346783
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B.
Arnold E; Yuan Y; Iloeje U; Cook G
Appl Health Econ Health Policy; 2008; 6(4):231-46. PubMed ID: 19382822
[TBL] [Abstract][Full Text] [Related]
20. Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation.
Jones J; Shepherd J; Baxter L; Gospodarevskaya E; Hartwell D; Harris P; Price A
Health Technol Assess; 2009 Jul; 13(35):1-172, iii. PubMed ID: 19607759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]